P3 Health Partners Inc. Class A Common Stock

Item 1A. Risk Factors. 

Except as described below, there have been no material changes to the risk factors previously disclosed in Part I, Item 1A., Risk Factors of our 2023 Form 10-K. You should carefully consider the risk factors included below and discussed in our 2023 Form 10-K, which could materially affect our business, financial condition or future results.

Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our securities.

We are required to meet the continued listing requirements of the Nasdaq Capital Market and if we fail to satisfy such continued listing requirements, Nasdaq may take steps to delist our securities. For example, on May 15, 2024, we received a deficiency letter (the Deficiency Letter) from the listing qualifications department of Nasdaq indicating that, for the prior thirty-one consecutive business days, the bid price for our Class A common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have beenwere granted an initial period of 180 calendar days, or until November 11, 2024, to regain compliance with the Bid Price Rule. The Deficiency Letter states that the Nasdaq staff will provide written notification that we have aWe did not achieved compliance with the Bid Price Rule if at anyprior to this time before.

On November 112, 2024, the bid price of our Class A common stock closes at $1.00 per share or more for a minimum of ten consecutive business days.

IfNasdaq notified us that we do not regain compliance with the Bid Price Rule by November 11, 2024, we may be ewere eligible for an additional 180 calendar day compliance peperiod. To qualify for this additional 180 day period, we would be required to mee to regain compliance with the Bid Price Rule as we met the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would

P3 Health Partners Inc. | Q3 2024 Form 10-Q | 43

aneed tod have provided written notice oto Nasdaq of our intention to cure the deficiency during the second compliance period. Howe by effecting a reverse stock split, if it appears tonecessary.

We intend to actively monitor the Nasdaq staff that we would not be aclosing bid price of our Class A common stock and will consider all available to cure thoptions to regain compliance with the Bid Price Rule deficiency, or if we are ot, which may include seeking stockholder approval to effect a reverse stock split. However, therwise not eligible, Nasdaq e can be no assurance that any such reverse stock split, if approved by the stockholders and implemented, would notify usincrease that oe market price of our securities would be subject to delisting. In Class A common stock in proportion to the reverse split ratio or result in a sustained increase in the event market price of such a notificaour Class A common stock. In addition, we may appealit is possible that the Nasdaq staffs determination to delist oreduced number of issued shares of Class A common stock resulting from such a reverse stock split could adversely affect the liquidity of our securitiesClass A common stock. There can also be no assurance that the Nasdaq staff would grant our requesany actions that we take will be successful in restoring our compliance with the Bid Price Rule or will prevent for continued liuture non-compliance therewith. There is also no assurance that we will maintain compliance with the other listing subsrequent to anirements of The Nasdaq Capital Market or that we will be successful in appealing any delisting notificdetermination.

Delisting from the Nasdaq Capital Market would cause us to pursue eligibility for trading of these securities on other markets or exchanges, or on the pink sheets. In such case, our stockholders ability to trade, or obtain quotations of the market value of our Class A common stock would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of our Class A common stock. There can be no assurance that our securities, if delisted from the Nasdaq Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the over-the-counter markets or the pink sheets. Delisting from the Nasdaq Capital Market, or even the issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market liquidity of our

P3 Health Partners Inc. | Q2 2024 Form 10-Q | 42

ssecurities, decrease securities analysts coverage of us or diminish investor confidence. Moreover, there is no assurance that any actions that we take will be successful in restoring our compliance with the Bid Price Rule or will prevent future non-compliance therewith. There is also no assurance that we will maintain compliance with the other listing requirements of The Nasdaq Capital Market.